• G P Sutton.
• Department of Obstetrics and Gynecology, Indiana University Hospital, Indianapolis.
• Semin. Oncol. 1994 Aug 1; 21 (4 Suppl 7): 32-6.

AbstractIn women with recurrent epithelial ovarian cancer, secondary treatment options include surgery and chemotherapy. Surgery should be considered in patients with persistent disease at the time of second-look laparotomy and before chemotherapy in those whose disease recurs following long-term remission. With regard to secondary chemotherapy, active agents include cisplatin, carboplatin, ifosfamide, and paclitaxel. The effectiveness of hexamethylmelamine as salvage therapy is less clear, although it may be of use in patients who relapse soon after receiving primary platinum chemotherapy. Patients who receive platinum therapy initially and relapse after long periods of remission often respond to second-line platinum treatment. Ifosfamide may be effective in patients receiving one or two prior cisplatin-containing regimens, but is contraindicated in those with hepatic or renal insufficiency. Paclitaxel is the drug of choice for patients who have developed primary resistance to platinum therapy.

14 keywords...

hide…